• Evonik is driving digitalization in the cosmetic industry
  • mySkin’s unique handheld device “OKU” measures a variety of skin properties and recommends care products
  • Breakthrough in how consumers can measure and improve their skin

Evonik has invested in the Jersey City (NJ, USA) based skin technology startup mySkin, Inc. through its venture capital unit and now holds a minority stake in the company. The transaction took place as part of a Series A financing round. The parties have agreed not to disclose the amount of the investment. “mySkin’s disruptive technology will strengthen our Health & Care Growth Engine while at the same time driving digitalization in the cosmetic industry”, said Lutz Stoeber, responsible for Evonik’s venture capital activities in North America.

mySkin facilitates a breakthrough in how consumers can measure and improve their skin. The company has developed a unique hand-held device – named OKU – which is the world’s first mobile-connected skin coach. OKU measures various properties of the skin. For the first time, reliable direct skin measurements lead to a recommendation of care products, based on data evaluation and the independent experience of other users with a similar skin type as well as lifestyle and dietary guidance to help the consumer get their skin into its youthful best.

“mySkin’s technology offers the possibility of getting a direct insight into how active ingredients perform in cosmetic products at the consumer level,” said Tammo Boinowitz, head of Evonik’s Personal Care Business Line. “The investment supports our strategy of supplying our cosmetic industry customers with a wide range of specialty technology solutions.” Evonik is one of the globally leading ingredient suppliers to the Personal Care industry. The product portfolio consists of high-end active ingredients, technological specialties, and base products for cosmetic applications. Evonik owns valuable know-how and expertise related to the development, customization, manufacture, marketing and application of products used as ingredients in cosmetic formulations.

Read more…

Recent Posts

Unlocking Precision in Dermatology Trials: The Impact of Optical Coherence Tomography for CROs

In the dynamic landscape of dermatology research and development, Clinical Research Organizations (CROs) play a…

Testing trends Webinar – Discover all the news around the evaluation at NYSCC

Explore Trends and Innovations at NYSCC To register, click here   📅 on Tuesday May…

Roger Guillemin: Neuroscientist who Showed How the Brain Controls Hormones via Nature

Roger Guillemin identified the molecules in the brain that control the production of hormones in…